SINT · Sintx Technologies, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $380.0K | - | $208.0K | $151.0K | $369.0K | - | $799.0K | $859.0K | $687.0K | - |
| Cost of Revenue | $236.0K | - | $115.0K | $94.0K | $246.0K | - | $210.0K | $224.0K | $223.0K | - |
| Gross Profit | $144.0K | - | $93.0K | $57.0K | $123.0K | - | $589.0K | $635.0K | $464.0K | - |
| R&D | $364.0K | - | $1.26M | $1.24M | $1.12M | - | $796.0K | $1.68M | $2.02M | - |
| SG&A | $2.54M | - | $2.10M | $1.31M | $1.16M | - | $802.0K | $1.07M | $1.12M | - |
| Total Operating Expenses | $3.35M | - | $3.45M | $2.72M | $2.51M | - | $7.00M | $3.35M | $3.66M | - |
| D&A | $68.0K | - | - | - | $95.0K | - | - | - | $256.0K | - |
| Operating Income | ($3.21M) | - | ($3.35M) | ($2.67M) | ($2.38M) | - | ($6.41M) | ($2.71M) | ($3.20M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.82M) | - | ($3.54M) | ($2.32M) | ($2.29M) | - | ($6.24M) | ($2.20M) | ($886.0K) | - |
| EPS - Basic | ($0.70) | - | ($3.46) | ($0.91) | ($1.29) | - | ($6.96) | ($3.49) | ($10.00) | - |
| EPS - Diluted | ($0.70) | - | ($3.46) | ($0.91) | ($1.29) | - | ($6.96) | ($3.61) | ($22.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.89M | $4.14M | $6.25M | $4.32M | $6.50M | $3.60M | $4.81M | $4.56M | $5.76M | $3.34M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $1.39M | $825.0K | $447.0K | $355.0K | $8.0K | $502.0K | $463.0K | $1.02M | $1.18M | $1.22M |
| Accounts Payable | $571.0K | $382.0K | $203.0K | $183.0K | $26.0K | $299.0K | $153.0K | $331.0K | $448.0K | $636.0K |
| Current Assets | $4.32M | $5.65M | $7.39M | $5.55M | $7.62M | $4.77M | $6.33M | $5.86M | $7.51M | $5.53M |
| Total Assets | $7.81M | $9.51M | $11.36M | $9.20M | $11.45M | $9.41M | $11.30M | $15.30M | $17.56M | $15.37M |
| Current Liabilities | $4.17M | $3.73M | $4.35M | $2.16M | $2.21M | $1.98M | $2.08M | $3.02M | $4.09M | $2.91M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.91M | $6.58M | $7.30M | $5.21M | $5.36M | $5.52M | $5.72M | $6.45M | $7.63M | $6.59M |
| Stockholders' Equity | $904.0K | $2.93M | $4.07M | $3.99M | $6.09M | $3.89M | $5.58M | $8.85M | $9.93M | $8.77M |
| Retained Earnings | ($294.92M) | ($292.10M) | ($289.89M) | ($286.35M) | ($284.03M) | ($281.74M) | ($280.04M) | ($273.80M) | ($271.60M) | ($270.71M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.49M) | - | - | - | ($1.30M) | - | - | - | ($2.73M) | - |
| Investing Cash Flow | ($7.0K) | - | - | - | ($63.0K) | - | - | - | ($173.0K) | - |
| Financing Cash Flow | $247.0K | - | - | - | $4.27M | - | - | - | $5.33M | - |
| CapEx | $7.0K | - | - | - | $59.0K | - | - | - | $174.0K | - |
| Free Cash Flow | ($2.50M) | - | - | - | ($1.36M) | - | - | - | ($2.91M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 37.9% | - | 44.7% | 37.7% | 33.3% | - | 73.7% | 73.9% | 67.5% | - |
| Operating margin | -843.9% | - | -1613.0% | -1764.9% | -645.8% | - | -802.0% | -315.5% | -465.4% | - |
| EBITDA margin | -826.1% | - | - | - | -620.1% | - | - | - | -428.1% | - |
| Net margin | -742.4% | - | -1701.4% | -1535.1% | -621.1% | - | -780.9% | -256.6% | -129.0% | - |
| Free cash flow margin | -657.4% | - | - | - | -368.6% | - | - | - | -423.1% | - |
| FCF / Net income | 0.89 | - | - | - | 0.59 | - | - | - | 3.28 | - |
| R&D / Revenue | 95.8% | - | 607.7% | 819.9% | 302.4% | - | 99.6% | 195.2% | 293.9% | - |
| SG&A / Revenue | 667.1% | - | 1010.6% | 867.5% | 314.4% | - | 100.4% | 124.8% | 163.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -36.1% | - | -31.1% | -25.2% | -20.0% | - | -55.2% | -14.4% | -5.0% | - |
| Return on equity | -312.1% | - | -87.0% | -58.1% | -37.6% | - | -111.8% | -24.9% | -8.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.04 | 1.51 | 1.70 | 2.57 | 3.45 | 2.41 | 3.04 | 1.94 | 1.84 | 1.90 |
| Quick ratio | 0.70 | 1.29 | 1.60 | 2.41 | 3.44 | 2.15 | 2.82 | 1.60 | 1.55 | 1.48 |
| Cash ratio | 0.45 | 1.11 | 1.44 | 2.00 | 2.94 | 1.82 | 2.31 | 1.51 | 1.41 | 1.15 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 8.64 | 3.25 | 2.79 | 2.31 | 1.88 | 2.42 | 2.03 | 1.73 | 1.77 | 1.75 |
| Liabilities / Assets | 0.88 | 0.69 | 0.64 | 0.57 | 0.47 | 0.59 | 0.51 | 0.42 | 0.43 | 0.43 |
| Efficiency | ||||||||||
| Asset turnover | 0.05 | - | 0.02 | 0.02 | 0.03 | - | 0.07 | 0.06 | 0.04 | - |
| Inventory turnover | 0.17 | - | 0.26 | 0.26 | 30.75 | - | 0.45 | 0.22 | 0.19 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 2156d | - | 1419d | 1378d | 12d | - | 805d | 1662d | 1925d | - |
| Days payable outstanding | 883d | - | 644d | 711d | 39d | - | 266d | 539d | 733d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 11.1x | - | 3.0x | 2.0x | 0.8x | - | 0.5x | 0.4x | 34.7x | - |
| P / S | 26.4x | - | 58.3x | 54.1x | 12.8x | - | 3.7x | 3.9x | 501.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 3.0% | - | -74.0% | -82.4% | -46.3% | - | 17.8% | 69.1% | 27.5% | - |
| Revenue CAGR (3y) | -11.0% | - | -21.3% | -14.3% | 42.0% | - | 49.5% | 104.1% | 89.5% | - |
| Revenue CAGR (5y) | 30.3% | - | 25.8% | -5.8% | 12.3% | - | 35.8% | 38.8% | 47.9% | - |
| Gross profit growth (YoY) | 17.1% | - | -84.2% | -91.0% | -73.5% | - | 5.0% | 57.2% | 10.2% | - |
| Operating income growth (YoY) | -34.6% | - | 47.6% | 1.7% | 25.5% | - | -77.3% | 21.8% | 10.1% | - |
| Net income growth (YoY) | -23.1% | - | 43.3% | -5.2% | -158.7% | - | -95.6% | 10.2% | -202.4% | - |
| EPS growth (YoY) | 45.7% | - | 50.3% | 74.8% | 94.1% | - | -759.3% | -362.8% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -83.7% | - | - | - | 53.2% | - | - | - | 43.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -85.2% | -24.8% | -27.1% | -54.9% | -38.6% | -55.6% | -47.8% | -36.0% | -37.7% | 53.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$1.02M totalProduct$729.0K · 71.6%
Grant And Contract$289.0K · 28.4%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Sintx Technologies against the 5 most active filers in the same SIC group.